Patient presents with symptoms consistent with type 2 diabetes mellitus, including polyuria, polydipsia, and polyphagia.  The patient reports recent unintentional weight loss and fatigue.  Fasting blood glucose of 142 mgdL and HbA1c of 7.8% confirm the diagnosis of type 2 diabetes.  Review of systems reveals no significant comorbidities at this time.  Assessment includes evaluation of cardiovascular risk factors, including hypertension, dyslipidemia, and family history.  Patient education provided regarding lifestyle modifications, including diet, exercise, and blood glucose monitoring.  Mounjaro (tirzepatide) prescribed at an initial dose of 2.5 mg subcutaneously once weekly, with titration planned based on glycemic response and tolerability.  Patient counseled on potential side effects of Mounjaro, including nausea, vomiting, and diarrhea, and instructed to report any adverse events.  Follow-up appointment scheduled in four weeks to monitor efficacy, assess for adverse effects, and adjust medication dosage as needed.  Diabetes management plan discussed, including medication adherence, self-monitoring of blood glucose, and the importance of regular follow-up appointments.  Diagnosis codes: E11.9 (Type 2 diabetes mellitus without complications), Z79.84 (Long term current drug therapy).  Procedure codes will be determined based on the services provided during the visit, potentially including 99213 (Office or other outpatient visit for the evaluation and management of an established patient) or similar codes, depending on complexity.